We still await good data on the transmissibility of the Indian variants of Sars-CoV-2, something the government insists is vital as to whether the full reopening of the economy and society can go ahead as planned on 21 June. But we do now have some data on efficacy of the Pfizer and AstraZeneca vaccines against the Indian variant B.1.617.2
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in